Researchers found that a new combination treatment for platinum-resistant ovarian cancer, involving the drug azenosertib and the chemotherapy paclitaxel, shows promising results. In a recent clinical trial, the combination achieved a 39% overall response rate, meaning that nearly four in ten patients experienced a reduction in their tumors. For those receiving a specific intermittent dose of azenosertib, the response rate was even higher at 50%, with patients enjoying a median duration of response lasting over nine months.

This finding is significant for individuals facing ovarian cancer, particularly those whose cancer has not responded to previous treatments. The combination therapy not only appears effective but also has a manageable safety profile, with low rates of severe side effects. This could mean better treatment options for women battling this challenging form of cancer, leading to improved quality of life and potentially longer survival times.

The evidence comes from an early-stage Phase 1b trial that included 46 patients who had all previously received paclitaxel. While the results are encouraging, it’s important to note that this is preliminary data, and further studies are needed to confirm these findings and establish the treatment’s long-term effectiveness and safety. The trial is part of a larger effort to explore azenosertib’s potential across various cancer types, which may open doors for more personalized treatment strategies in the future.

For now, if you or someone you know is dealing with ovarian cancer, staying informed about new treatment options like this combination therapy could be beneficial. Discussing these developments with a healthcare provider may help in making informed treatment decisions.

Source: globenewswire.com